A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes (J3R-MC-YDAL)

未提供0 个研究点目标入组 900 人开始时间: 待定

适应症

试验速览

暂无简介。

•Are on stable incretin therapy at screening
•With persistent obesity or overweight defined as:
•>=30 kg/m2 OR
•>=27 kg/m2 with at least one existing obesity related complication at screening:
•hypertension
•dyslipidemia
•obstructive sleep apnea
•cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
•type 2 diabetes
•Have a stable body weight (<5% body weight change) at screening

•Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
•Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
•Have type 1 diabetes
•Have taken any of the following antihyperglycemic medications within 90 days before screening:
•dipeptidyl peptidase-4 (DPP-4) inhibitors
•amylin analogs
•Have had within 90 days prior to screening:
•heart attack
•coronary artery revascularization
•unstable angina, or
•hospitalization due to congestive heart failure
•Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

发起方

未提供